应杰儿,刘碧霞,钟海均.转移性结直肠癌西妥昔单抗治疗的疗效及安全性[J].肿瘤学杂志,2012,18(5):345-348.
转移性结直肠癌西妥昔单抗治疗的疗效及安全性
The Efficacy and Safety of Cetuximab in the Treatment for Metastatic Colorectal Cancer
投稿时间:2012-01-03  
DOI:10.11735/j.issn.1671-170X.2012.5.B2012003
中文关键词:  西妥昔单抗  结直肠肿瘤  K-ras  药物疗法
英文关键词:cetuximab  colorectal neoplasms  K-ras  drug therapy
基金项目:浙江省医药卫生科技计划项目(2008B198)
作者单位
应杰儿 浙江省肿瘤医院 
刘碧霞 浙江省肿瘤医院 
钟海均 浙江省肿瘤医院 
摘要点击次数: 2690
全文下载次数: 1461
中文摘要:
      摘 要:[目的] 观察西妥昔单抗对K-ras野生型转移性结直肠癌的疗效和不良反应。[方法] 对34例接受西妥昔单抗单药(1例)或联合化疗(33例)治疗的K-ras野生型转移性结直肠癌患者进行疗效及不良反应分析。[结果] 34例患者均可评价疗效及不良反应。全组有效率41.2%,中位无进展生存时间6.5个月,中位生存时间16.9个月。7例一线治疗患者有效率57.1%,中位无进展生存时间7.2个月,中位生存时间21.4个月。21例二线治疗患者,有效率38.1%,中位无进展生存时间6.9个月,中位生存时间15.7个月。6例三线或三线以上患者,有效率33.3%。最常见的不良反应为皮肤毒性,其次骨髓抑制,大多为Ⅰ~Ⅱ度。[结论] 国人K-ras野生型转移性结直肠癌患者中,西妥昔单抗联合化疗在一线、二线及多线治疗中均获得较好的客观缓解及疾病控制,同时不良反应可耐受。
英文摘要:
      Abstract:[Purpose] To investigate the efficacy and safety of cetuximab in the treatment for K-ras wild-type metastatic colorectal cancer. [Methods] The efficacy and toxicity of cetuximab alone(1 case) or combined(33 cases) chemotherapy in 34 cases with K-ras wild-type advanced colorectal cancer were analyzed. [Results] All the 34 patients were assessable for efficacy and toxicity. Of the whole group,the response rate (RR) was 41.2%,with the median progression-free survival(mPFS) 6.5 months,the median survival 16.9 months. Of 7 cases as the first-line treatment,RR was 57.1%,mPFS, 7.2 months and median survival, 21.4 months. Of 21 cases as second-line treatment,RR was 38.1%,mPFS, 6.9 months and the median survival,15.7 months. Of 6 cases as third-line treatment or above,RR was 33.3%.The most common toxicities were skin toxicity and bone marrow suppression,however most of them were grade Ⅰ~Ⅱ.[Conclusion] In the K-ras wild-type Chinese patients with metastatic colorectal cancer,cetuximab combined chemotherapy as first line,second-line and multi-line treatment have showed a good objective response and disease control,and the toxicities are tolerable.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器